Stanford, CANCT04256018Now EnrollingIRB Ready

Sezary Syndrome Clinical Trial in Stanford, CA

Access cutting-edge sezary syndrome treatment through this phase 2 clinical trial at a research site in Stanford. Study-provided care at no cost to qualified participants.

Sponsored by Stanford University

Quick Self-Assessment

See if you qualify for this Stanford location

Preparing your pre-screening questions…

Expert Care in Stanford

Access sezary syndrome specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related sezary syndrome treatment provided free

Apply for This Stanford Location

Check if you qualify for this sezary syndrome clinical trial in Stanford, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Stanford

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Stanford site if eligible
  4. 4Begin participation

About This Sezary Syndrome Study in Stanford

The purpose of this study is to determine the efficacy of the combination of LD-TSEBT and mogamulizumab in patients with MF and SS. And to evaluate the secondary measures of clinical benefit of the combination therapy and to evaluate the safety and tolerability of the combination in patients with MF and SS.

Sponsor: Stanford University

Who Can Participate

Inclusion Criteria

Stages IB-IV MF or SS
Stages IB-IV MF or SS
At least 1 prior standard-of-care therapy
Prior LD-TSEBT (\> 3 months prior) and prior mogamulizumab is allowed, as long as progressive disease (PD) did not occur while on therapy, and did not discontinue due to toxicities
≥ 18 years of age
ECOG performance status of 0 to 2
All clinically-significant toxic effects of prior cancer therapy resolved to Grade ≤ 1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI-CTCAE, v 5.0).
MF and a known history of non-complicated staphylococcus colonization/infection is eligible provided that stable doses of prophylactic antibiotics continue.
The following minimum wash-out from previous treatments are required (prior to 1st day of treatment), if applicable. • ≥ 2weeks for retinoids, interferons, Vorinostat, romidepsin, pralatrexate, or other systemic anti-cancer/CTCL therapies • ≥ 2 weeks for phototherapy, local radiation therapy • ≥ 2 weeks for topical therapy (including topical steroid, retinoid, nitrogen mustard, or imiquimod) • ≥ 12 weeks for total skin electron beam therapy • \> 12 weeks for alemtuzumab • Rapidly progressive malignant disease may be enrolled prior to above periods after discussion with the Protocol Director.
Adequate hematologic function • Absolute neutrophil count (ANC) ≥ 1,000 cells/μL (≥ 1,000/mm3) • Platelets ≥ 75,000 cells/μL (≥ 75,000/mm3).
Adequate hepatic function
Bilirubin ≤ 1.5 times the specific institutional upper limit of normal (ULN). Exception: If Gilbert's syndrome; then ≤ 5 times ULN.
Aspartate transaminase (AST) and alanine transaminase (ALT) each ≤ 2.5 x ULN; or ≤ 5.0 x ULN in the presence of known hepatic involvement by CTCL.
Adequate renal function • Calculated creatinine clearance ≥ 30 mL/min using the Cockcroft-Gault formula.
If prior allogeneic hematopoietic stem cell transplant (HSCT), then must be free of graft-vs-host disease (GvHD) and receiving immunosuppressive therapy.
Women of childbearing potential (WOCBP) must have a negative pregnancy test.
WOCBP must agree to use effective contraception during the study and for 3 months after the last dose.
Male participants and their female partners of child bearing potential must be willing to use an appropriate method of contraception during the study and for 3 months after the last dose.

Exclusion Criteria

MF with limited disease (Stage IA) or central nervous system (CNS) disease
Concomitant corticosteroid use. (with the exception that topical steroid and oral prednisone are allowed at ≤ 20 mg/day, if patient has been on a stable dose for at least 2 weeks prior to 1st day of treatment)
Pregnant or breastfeeding
Active autoimmune disease or history deemed by the investigator to be clinically significant
Known human immunodeficiency virus (HIV) positivity; or active hepatitis B or C.
Active herpes simplex or herpes zoster. Those receiving prophylaxis for herpes and who started taking medication at least 30 days prior to the Screening Visit, and have no active signs of active infection, and whose last active infection was more than 6 months ago, may enter the study, and should continue to take the prescribed medication for the duration of the study.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Stanford?

Yes, this clinical trial (NCT04256018) has an active research site in Stanford, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Sezary Syndrome Treatment Options in Stanford, CA

If you're searching for sezary syndrome treatment options in Stanford, CA, this clinical trial (NCT04256018) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Stanford research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced sezary syndrome specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all sezary syndrome clinical trials near you to find additional studies recruiting in your area.

More Myalgic Encephalomyelitis Trials in Stanford, CA

See all myalgic encephalomyelitis clinical trials recruiting in Stanford — not just this study.

Browse Myalgic Encephalomyelitis Trials in Stanford →

Browse More Trials by Condition

Myalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Stanford?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Stanford, CA